Health-related quality of life in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation with tyrosine kinase inhibitors treatment: a systematic review
Open Access
- 16 October 2019
- journal article
- review article
- Published by GP Innovations Pvt. Ltd. in International Journal of Research in Pharmaceutical Sciences
- Vol. 10 (4) , 2898-2906
Abstract
Tyrosine Kinase Inhibitors (TKIs) have been recommended by the National Comprehensive Cancer Network (NCCN) as first-line therapy in Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutations. In addition to prolonging Progression-Free Survival and Overall Survival, one of the treatment goals also considers improving the health-related quality of life (HRQOL), which can help to achieve the patients' treatment targets. Several systematic review studies related to HRQOL in advanced NSCLC patients have already been carried out, but there are only a few studies of HRQOL in NSCLC patients who experience EGFR mutations and are treated with TKIs in their specific treatment. This Systematic review aims to provide an overview of the impact of TKIs on HRQOL. Relevant studies were identified from Science Direct, PubMed, and Scopus. They were limited to articles explaining TKIs as first-line therapy, written in English, not a systematic review or meta-analysis, and not containing incomplete text. Electronic data-based search produced 112 articles, with 21 articles matched the title and abstract, yet only nine articles met the inclusion and exclusion to be reviewed. In general, the impact of HRQOL on TKIs is better than platinum and placebo-based chemotherapy. Afatinib, erlotinib, and gefitinib further improved HRQOL compared to platinum and placebo-based chemotherapy seen from the improvements in symptoms, physical function, and social function scale. However, gefitinib vs erlotinib showed no significant difference in patients’ the quality of life. TKIs provide better HRQOL than platinum and placebo-based chemotherapy.Keywords
This publication has 19 references indexed in Scilit:
- Disease progression impacts health-related quality of life in amyotrophic lateral sclerosisJournal of the Neurological Sciences, 2019
- Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort studyLung Cancer, 2017
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyThe Lancet Oncology, 2016
- Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung CancerJournal of Thoracic Oncology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyLung Cancer, 2013
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapyLung Cancer, 2012
- Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)Journal of Thoracic Oncology, 2011
- The impact of emotional well-being on long-term recovery and survival in physical illness: a meta-analysisJournal of Behavioral Medicine, 2011
- Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment optionsAnnals of Oncology, 2009